Clinical Trial Update: Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating cellular immunotherapy for COVID-19-related Acute Respiratory Distress Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Acute Respiratory Distress Syndrome, Covid19 | Phase 1, Phase 2 | Status: COMPLETED